Tell us a little bit about the design, how many patients, and when were the beta blockers discontinued and what was the follow-up?

right so we decided on a probe design prospective randomized open leg blood with a blinded endpoint random endpoint evaluation our endpoints were basically taken out of the national registries but also all endpoints were independently adjudicated by a two independent cardiologists by a committee And we enrolled in total together in Norway and in Denmark, together we enrolled over 5,500 patients.

The design was such that we should give the beta blocker no later than 14 days after the index event.

But in reality, the randomization occurred already at date two in median time.

And our total follow-up time was 3.5 years.

We had the advantage that we could blindedly monitor the event rate so that we were sure that the power of the study would be sufficient.

to show an outcome.

So, you know, in 2025 and beyond, do we give beta blockers post-MI? What's your feeling?